Evotec AG:Ad hoc: Evotec AG: Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

Wednesday, 18. May 2011 11:29
Evotec AG /
/
Ad hoc: Evotec AG: Phase II study with NR2B sub-type selective NMDA antagonist
in treatment-resistant depression voluntarily terminated
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, TecDAX, ISIN: DE
000 566480 9) and Roche today decided to voluntarily terminate the first proof-
of-concept study in treatment-resistant depression with their NR2B sub-type
selective NMDA antagonist EVT 101.


The decision to terminate this Phase II study was triggered by difficulties to
recruit patients under the current study protocol, resulting in the possibility
of inconclusive results. EVT101 was generally well tolerated in healthy
volunteers and patients enrolled so far. Difficulties in conducting this Phase
II study in treatment resistant depression, the need to sharpen the toxicology
profile and a potential requirement for an altered dosage scheme lead to an
overall delay in the programme. Based on this the parties concluded to terminate
the clinical development.

Evotec retains all rights in the EVT100 series, especially the back-up compound
EVT103 and will enter into partnering discussions for these assets in another
clinical development partnership. As advanced clinical development of drug
candidates is not part of Evotec's core business, Evotec does not intend to
pursue further clinical development of its in NR2B sub-type selective NMDA
antagonist without a partner.

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG,
Schnackenburgallee 114, 22525 Hamburg, Germany, Phone: +49.(0)40.560 81-242,
werner.lanthaler@evotec.com

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1516795]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.